GPT and metabolic dysfunction-associated steatohepatitis: For biomarkers like ALT, our preliminary exploratory subgroup analyses provide crucial distinction: a significant reduction was evident in the overall pool, but the effect was markedly stronger and highly homogeneous in trials enrolling biopsy-confirmed MASH patients (WMD = −14.50 U/L; I2 = 0%) compared to those with high-risk conditions like T2DM (WMD = −3.30 U/L; I2 = 77%; P for interaction < 0.00001).